At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of Type 2 Diabetes Mellitus
- ✕Bleeding disorders including gastrointestinal reflux disease, peptic ulcer disease, or any gastrointestinal bleeding
- ✕High blood pressure (uncontrolled hypertension)
- ✕History of Coronary Artery Disease or chest pain on exertion
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of Acute Combined Peroxisome Proliferator-Activated Receptors (PPAR) Alpha and Gamma Stimulation on Insulin Action in Humans
In Brief
A Phase 4 clinical trial evaluating Pioglitazone, Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the acute effects of the thiazolidinedione agent pioglitazone (which has combined PPAR alpha and gamma stimulation) on insulin's ability to suppress glucose production, stimulated glucose uptake, and impact a number of other metabolically important endpoints, including production of adiponectin (a protein hormone which regulates sugar levels and fatty acid breakdown) in subjects with type 2 diabetes.
Study Details
Timeline
Interventions
This was a randomized placebo-controlled crossover study in which subjects received both agents in random order, separated by a wash-out period. Following 10 or 21 days' intervention, subjects underwent a pancreatic clamp study.
This was a randomized placebo-controlled crossover study in which subjects received both agents in random order, separated by a wash-out period. Following 10 or 21 days' intervention, subjects underwent a pancreatic clamp study.
During the clamp procedure, glucose (a sugar) and insulin were infused with an IV catheter, and blood samples were collected periodically throughout the procedure to measure blood sugar levels and the levels of several hormones that are found in the body and are related to glucose metabolism.